Measurement of end points in heart failure trials: Jousting at windmills?

Mount Sinai Journal of Medicine

Volumn 71, Issue 5, 2004, Pages 298-304

  Hauptman, Paul J ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; End points; Heart failure

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN; INOTROPIC AGENT; MILRINONE; NORADRENALIN; PLACEBO; SPIRONOLACTONE;

ARTICLE; CONGESTIVE HEART FAILURE; DIASTOLE; DRUG APPROVAL; DRUG EFFICACY; DRUG USE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE SIZE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE VOLUME; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; MORTALITY; PREVALENCE; QUALITY OF LIFE; SURVIVAL;

BIOMEDICAL RESEARCH; CAUSE OF DEATH; CHRONIC DISEASE; ENDPOINT DETERMINATION; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 7444269582     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Cervantes M. The adventures of Don Quixote de la Mancha. New York: Dodd Mead and Company; 1962.
2. American Heart Association. Heart disease and stroke statisticsC2004 update. Dallas (TX): American Heart Association; 2003. Available from: www.americanheart.org/presenter.jhtml?identifier=1928 (Accessed 6/1/04).
3. Gillum RF. Epidemiology of heart failure in the United States. Am Heart J 1993; 126:1042-1047.
4. Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey: 1985 to 1995. Am Heart J 1999; 137:352-360.
5. Croft JB, Giles WH, Pollard RA, et al. National trends in the initial hospitalization for heart failure. J Am Geriatr Soc 1997; 45(3):270-275.
6. Senni M, Tibouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Int Med 1999; 159:29-34.
7. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure; the Framingham study. J Am Coll Cardiol 1993; 22(Suppl A):6A-13A.
8. Zannad F, Braincon S, Juilliere Y, et al. Incidence, clinical and etiologic features and outcomes of advanced chronic heart failure: the EPICAL study. J Am Coll Cardiol 1999; 33:734-742.
9. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996; 94(11): 2793-2799.
10. Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, et al., on behalf of the Beta-blocker Evaluation of Survival Trial (BEST) Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344:1659-1667.
11. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations and well-being in patients with heart failure: the Metroprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000; 283:1295-1302.
12. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993; 22:955-962,
13. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
14. Havranek E, LaPuerta P, Simon TA, et al. A health perception score predicts cardiac events in patients with heart failure: results from the IMPRESS trial. J Card Fail 2001; 7(2):153-157.
15. Hinkle LE, Thaler HT. Clinical classification of cardiac deaths. Circulation 1982; 65:457-464.
16. Packer M. Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure. Circulation 1992; 85(Suppl):I50-I56.
17. Cleland JG, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail 1999; 1(1):41-45.
18. Narang R, Cleland JGF, Erhardt L, et al. Mode of death in chronic heart failure: a request and proposition for more accurate classification. Eur Heart J 1996; 17:1390-1403.
19. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
20. Poole-Wilson PA, Uretsky BF, Thygesen K, et al. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003; 89:42-48.
21. Derfler MC, Jacob MC, Wolf RE, Hauptman PJ. Death from congestive heart failure: experience of a disease management program [abstract]. J Card Fail 2003; 9(5):595.
22. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273:1450-1456.
23. Cleland JG. Beta-blockers for heart failure: why, which, when, and where. Med Clin N Am 2003; 87:339-371.
24. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
25. Packer M. Proposal for a new clinical endpoint to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 2001; 7:176-182.
26. Franciosa JA, Taylor AL, Cohn JN, et al. A-HeFT Investigators. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail 2002; 8:128-1235.
27. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992; 124(4):1017-1025.
28. Konstam MA, Udelson JE, Anand IS, Cohn JN. Ventricular remodeling in heart failure: a credible surrogate endpoint. J Cardiac Failure 2003; 9:350-353.
29. Lipicky RJ, Packer M. Role of surrogate end points in the evaluation of drugs for heart failure. J Am Coll Cardiol 1993; 22(4 Suppl A): 179A-184A.
30. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. The Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Am J Cardiol 1988; 61(8):501-509.
31. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321(6):406-412.
32. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomized study of effects of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997; 349:971-977.
33. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 1993; 329:149-155.
34. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325:1468-1475.
35. Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators. Brit Heart J 1994; 72:226-230.
36. Udelson JE, Konstam MA. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. J Card Fail 2002; 8(6 Suppl): S465-S471.
37. Anand IS, Florea VG, Solomon SD, et al. Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials. J Card Fail 2002; 8:S452-S464.
38. Luderitz B, Jung W. Quality of life in patients with atrial fibrillation Arch Intern Med 2000; 160:1749-1757.
39. Konstam M, Dracup K, Baker D, et al. Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction. Clinical practice guideline No. 11. AHCPR Publication No. 94-0612. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services. June 1994.
40. Al-Kaade S, Hauptman PJ. Health-related quality of life measurement in heart failure: challenges for the new millennium. J Card Fail 2001; 7:194-201.
41. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994; 272:619-626.
42. Ni H, Toy W, Burgess D, et al. Comparative responsiveness of Short-Form 12 and Minnesota Living with Heart Failure Questionnaire in patients with heart failure. J Card Fail 2000; 6(2):83-91.
43. Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76:223-231.
44. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343(3):246B253. Errata in N Engl J Med 2000; 343(20):1504 and N Engl J Med 2000; 343(12):896.
45. Rector TS. Measurement of clinical efficacy in studies of heart failure. Circulation 1998; 97(7):707.
46. Packer M. The placebo effect in heart failure. Am Heart J 1990; 120:1579-1582.
47. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002:287:1531-1540.
48. Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:777-781.
49. Rose EAT, Gelijns AC, Moskowitz AJ, et al, for the REMATCH Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345:1435-1443.
50. Zafeiridis A, Jeevanandum V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998; 98:656-662.
51. Dipla K, Mattiello JA, Jeevanandum V, et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 1998; 97:2316-2322.
52. Bristow MR, Hershberger RE, Port JD, et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990; 82:I12-I25.
53. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999; 5:178-187.
54. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344:1351-1357.
55. Wedel H, Demets D, Deedwania P, on behalf of the MERIT-HF study group. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Am Heart J 2001; 142:502-511.
56. Cohn JN, Goldstein SO, Greenberg BH, et al, for the Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998; 339:1810-1816.
57. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335:1107-1114.
58. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997; 337:1569-1575.
59. Pfeffer MA, Domanski M, Verter J, on behalf of the PEACE investigators. The continuation of the prevention of events with angiotensin converting enzyme inhibition trial. Am Heart J 2001; 142:375-377.
60. Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? Lancet 1999; 354:1202-1204.
61. Poole-Wilson PA, Swedberg K, Cleland JG, et al.; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): ramdomised controlled trial. Lancet 2003; 362(9377):7-13.
62. Physicians Desk Reference, 56th edition, p3086. Montvale (NJ): Medical Economics Company; 2002.
63. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). 2001. American College of Cardiology Web Site. Available from: http://www.acc.org/clinical/guidelines/failure/hf_index.htm (Accessed 3/18/04)
64. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002; 162(15):1682-1688.
65. Messerli FH, Grodzicki T, Feng Z, et al. Antihypertensive therapy in the elderly: evidence based guidelines and the elderly. Arch Intern Med 1999; 159(15):1621-1622.